1 citations
,
September 2022 in “International Journal of Trichology” In this case report, a young adult male with resistant alopecia areata showed nearly 90% hair regrowth after 3 months of treatment with tofacitinib, alongside biotin supplementation, without any side effects observed.
8 citations
,
June 2022 in “Frontiers in Medicine” This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.
7 citations
,
March 2021 in “Journal of the American Academy of Dermatology” This study observed that some children and young adults with alopecia areata experienced flares during long-term tofacitinib treatment, despite initial successful hair regrowth.
11 citations
,
February 2021 in “Journal of Cosmetic Dermatology” This retrospective pilot study found that oral tofacitinib was more effective in treating alopecia areata than alopecia universalis, but relapses were common after treatment cessation.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” In this study, three children with severe alopecia treated with systemic tofacitinib showed significant hair regrowth, suggesting it may be a potential option for those unresponsive to conventional therapy.
79 citations
,
September 2018 in “Dermatologic therapy” This study found that treatment with oral tofacitinib, alone or with other therapies, was associated with clinical improvement in most patients with recalcitrant lichen planopilaris.
4 citations
,
July 2018 in “PubMed” This study reports significant hair regrowth in 11 patients with severe alopecia areata following longstanding treatment with oral tofacitinib and also highlights successful treatment using topical tofacitinib cream in one case.
24 citations
,
January 2018 in “International Journal of Trichology” This study found that oral tofacitinib was effective in promoting hair regrowth in patients with alopecia universalis, although further controlled studies are recommended to confirm its safety and efficacy.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” This study found that oral tofacitinib led to variable hair regrowth in patients with resistant alopecia areata, implying that longer treatment durations may be needed to fully assess its effectiveness.
16 citations
,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” This case study reports that a 23-year-old woman with alopecia universalis experienced complete hair regrowth after six months of treatment with tofacitinib, a JAK-3 inhibitor.
